Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies

Cancer Discov. 2016 Jan;6(1):17-9. doi: 10.1158/2159-8290.CD-15-1366.


Cross-presentation of tumor antigens represents a key pathway in antitumor immune responses that can be exploited to synergize not only with the already prominent "checkpoint blockade," but also with newer attempts to use T-cell stimulatory monoclonal antibodies in immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Neoplasm / metabolism
  • Dendritic Cells / immunology*
  • Humans
  • Immunotherapy
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • T-Lymphocytes / immunology


  • Antibodies, Monoclonal
  • Antigens, Neoplasm